← Back to Search

Monoclonal Antibodies

Dose 1 for Thermal Burn Pain

Phase 2

Waitlist Available

Research Sponsored by Regeneron Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-group, single-dose study of the efficacy of REGN475 in patients with pain due to thermal injury.

Eligible Conditions

Thermal Burn Pain

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in procedural pain intensity

Secondary outcome measures

Additional quality of life assessments

Cumulative analgesic usage

Weekly Patient-rated Global Impression of Change

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Dose 2Experimental Treatment1 Intervention

R475

Group II: Dose 1Experimental Treatment1 Intervention

R475

Group III: Dose 3Placebo Group1 Intervention

Placebo to match R475 dose

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor

626 Previous Clinical Trials

381,825 Total Patients Enrolled

SanofiIndustry Sponsor

2,170 Previous Clinical Trials

3,516,422 Total Patients Enrolled

Paul Tiseo, PhDStudy DirectorRegeneron Pharmaceuticals

3 Previous Clinical Trials

286 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury

2024. "Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01053702.

~0 spots leftby May 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.